Abstract
To examine the late effects and health-related quality of life of childhood cancer survivors (CCS) after radiotherapy (RT), we performed a cross-sectional survey using self-rating questionnaires. The subjects were divided into 3 groups: CCS treated with or without RT, and a general population matched for age, gender, residential area, and work status. The numbers in each group were 113, 72, and 1,000, respectively. The median ages of CCS at diagnosis and the time of the survey were 8 and 22 years, respectively. The mean final heights of males and females were significantly lower in CCS with RT than in the other 2 groups. Risk factors for a short stature were total body irradiation (TBI) [odds ratio (OR) 17.8, p < 0.001], spinal irradiation (OR 8.31, p = 0.033), and an age younger than 10 years at diagnosis. Late effects were observed in 68% of CCS with RT compared with 36% of CCS without RT. Multivariate analysis revealed that TBI was significantly associated with endocrine dysfunction (OR 12.3), skull and spinal irradiation with cognitive dysfunction (OR 16.1 and 11.5, respectively), and spinal irradiation with a short stature (OR 14.1), respectively. Physical dysfunction, psychological stress, and problems of social adaptation were observed in >50% of CCS with RT.
Similar content being viewed by others
References
Robison LL, Armstrong GT, Boice JD, Chow EJ, Davies SM, Donaldson SS, et al. The Childhood Cancer Survivor Study: a National Cancer Institute-supported resource for outcome and intervention research. J Clin Oncol. 2009;27(14):2308–18. doi:10.1200/JCO.2009.22.3339.
Hawkins MM, Lancashire ER, Winter DL, Frobisher C, Reulen RC, Taylor AJ, et al. The British Childhood Cancer Survivor Study: objectives, methods, population structure, response rates and initial descriptive information. Pediatr Blood Cancer. 2008;50(5):1018–25. doi:10.1002/pbc.21335.
Geenen MM, Cardous-Ubbink MC, Kremer LC, van den Bos C, van der Pal HJ, Heinen RC, et al. Medical assessment of adverse health outcomes in long-term survivors of childhood cancer. JAMA. 2007;297(24):2705–15.
Diller L, Chow EJ, Gurney JG, Hudson MM, Kadin-Lottick NS, Kawashima TI, et al. Chronic disease in the Childhood Cancer Survivor Study cohort: a review of published findings. J Clin Oncol. 2009;27(14):2339–55. doi:10.1200/JCO.2008.21.1953.
Ishida Y, Honda M, Ozono S, Okamura J, Asami K, Maeda N, et al. Late effects and quality of life of childhood cancer survivors: Part 1 Impact of the stem cell transplantation. Int J Hematol. 2010. doi:10.1007/s12185-010-0584-y.
Green DM, Sklar CA, Boice JD Jr, Mulvihill JJ, Whitton JA, Stovall M, et al. Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivor Study. J Clin Oncol. 2009;27(14):2374–81. doi:10.1200/JCO.2008.21.1839.
Hudson MM, Mulrooney DA, Bowers DC, Sklar CA, Green DM, Donaldson SS, et al. High-risk populations identified in Childhood Cancer Survivor Study investigations: implications for risk-based surveillance. J Clin Oncol. 2009;27(14):2405–14. doi:10.1200/JCO.2008.21.1516.
Meadows AT, Friedman DL, Neglia JP, Mertens AC, Donaldson SS, Stovall M, et al. Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort. J Clin Oncol. 2009;27(14):2356–62. doi:10.1200/JCO.2008.21.1920.
Maeda M. Late effects of childhood cancer: life-threatening issues. J Nippon Med Sch. 2008;75(6):320–4. doi:JST.JSTAGE/jnms/75.320[pii].
Miyoshi Y, Ohta H, Hashii Y, Tokimasa S, Namba N, Mushiake S, et al. Endocrinological analysis of 122 Japanese childhood cancer survivors in a single hospital. Endocr J. 2008;55(6):1055–63. doi:JST.JSTAGE/endocrj/K08E-075[pii].
Ishiguro H, Yasuda Y, Tomita Y, Shinagawa T, Shimizu T, Morimoto T, et al. Long-term follow-up of thyroid function in patients who received bone marrow transplantation during childhood and adolescence. J Clin Endocrinol Metab. 2004;89(12):5981–6.
Ishida Y, Honda M, Kamibeppu K, Ozono S, Iwai T, Kakee N, et al. Cross-sectional survey on the late effects and QOL of childhood cancer survivors, Part 1. J Jpn Pediatr Soc. 2010;114(4):665–75.
Gurney JG, Ness KK, Stovall M, Wolden S, Punyko JA, Neglia JP, et al. Final height and body mass index among adult survivors of childhood brain cancer: childhood cancer survivor study. J Clin Endocrinol Metab. 2003;88(10):4731–9.
Chow EJ, Friedman DL, Yasui Y, Whitton JA, Stovall M, Robison LL, et al. Decreased adult height in survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Pediatr. 2007;150(4):370–5, 375.e1. doi:10.1016/j.jpeds.2006.11.036.
Noorda EM, Somers R, van Leeuwen FE, Vulsma T, Behrendt H. Adult height and age at menarche in childhood cancer survivors. Eur J Cancer. 2001;37(5):605–12. doi:S095980490000438X[pii].
Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006;355(15):1572–82. doi:10.1056/NEJMsa060185.
Nandagopal R, Laverdiere C, Mulrooney D, Hudson MM, Meacham L. Endocrine late effects of childhood cancer therapy: a report from the Children’s Oncology Group. Horm Res. 2008;69(2):65–74. doi:10.1159/000111809.
Chemaitilly W, Boulad F, Sklar C. Endocrine complications of childhood hematopoietic stem-cell transplantation. In: Kline R, editor. Pediatric hematopoietic stem cell transplantation. New York: Informa Healthcare USA; 2006. p. 287–398.
Rutter MM, Rose SR. Long-term endocrine sequelae of childhood cancer. Curr Opin Pediatr. 2007;19(4):480–7. doi:10.1097/MOP.0b013e3282058b56-00008480-200708000-00017[pii].
Sanders JE. Endocrine complications of high-dose therapy with stem cell transplantation. Pediatr Transplant. 2004;8(Suppl 5):39–50.
Askins MA, Moore BD 3rd. Preventing neurocognitive late effects in childhood cancer survivors. J Child Neurol. 2008;23(10):1160–71. doi:10.1177/0883073808321065.
Brownstein CM, Mertens AC, Mitby PA, Stovall M, Qin J, Heller G, et al. Factors that affect final height and change in height standard deviation scores in survivors of childhood cancer treated with growth hormone: a report from the childhood cancer survivor study. J Clin Endocrinol Metab. 2004;89(9):4422–7.
Larson DL, Kroll S, Jaffe N, Serure A, Goepfert H. Long-term effects of radiotherapy in childhood and adolescence. Am J Surg. 1990;160(4):348–51.
Kony SJ, de Vathaire F, Chompret A, Shamsaldim A, Grimaud E, Raquin MA, et al. Radiation and genetic factors in the risk of second malignant neoplasms after a first cancer in childhood. Lancet. 1997;350(9071):91–5. doi:10.1016/S0140-6736(97)01116-1.
Neglia JP, Friedman DL, Yasui Y, Mertens AC, Hammond S, Stovall M, et al. Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study. J Natl Cancer Inst. 2001;93(8):618–29.
Han JW, Kwon SY, Won SC, Shin YJ, Ko JH, Lyu CJ. Comprehensive clinical follow-up of late effects in childhood cancer survivors shows the need for early and well-timed intervention. Ann Oncol. 2009;20(7):1170–7. doi:10.1093/annonc/mdn778.
Acknowledgments
The institutions that provided patient data and recruited CCS to the survey are listed in Table 1. This study was supported by research grants from the Japanese Ministry of Health, Labour and Welfare (Grant No. 18-14: “Study of quality of life and prognosis in childhood cancer survivors and establishment of a long-term follow-up system”).
Conflict of interest statement
The authors declare no financial interests.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Ishida, Y., Sakamoto, N., Kamibeppu, K. et al. Late effects and quality of life of childhood cancer survivors: Part 2. Impact of radiotherapy. Int J Hematol 92, 95–104 (2010). https://doi.org/10.1007/s12185-010-0611-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12185-010-0611-z